TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Trade (domestic/foreign) TRD

Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals and "paired port" issue.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; U.S. Customs & Border Protection; Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO)

Health Issues HCR

H.R. 3590, Patient Protection & Affordable Care Act and H.R. 4872, Healthcare & Education Affordability Reconciliation Act (provisions relating to pharmaceuticals).

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Patent & Trademark Office (PTO); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Customs & Border Protection; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: H.R. 4872 (111th), H.R. 3590 (111th)

Copyright/Patent/Trademark CPT

H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; and S. 369, Preserve Access to Affordable Generics Act.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); U.S. Customs & Border Protection

Bills named: S. 515 (111th), S. 369 (111th), H.R. 1260 (111th), H.R. 1706 (111th), S. 610 (111th)

Pharmacy PHA

S. 301, Physicians Payments Sunshine Act of 2009; H.R. 1859 & S. 767, Independent Drug Education & Outreach Act of 2009; H.R. 1427 & S. 726, Promoting Innovation & Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to the "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA")

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Patent & Trademark Office (PTO); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); U.S. Customs & Border Protection; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 1548 (111th), S. 726 (111th), S. 767 (111th), S. 301 (111th), H.R. 1427 (111th), H.R. 1859 (111th)